CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the
Company has been invited to present at the William Blair and Company’s 29th
Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at
the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive
Officer, and Bill Motto, Executive Chairman of the Board, are scheduled
to present. A question and answer session will follow the Company’s
presentation. The information provided during the session may not have
been previously disclosed.
Meridian invites investors to listen to management’s remarks on the
Company’s website at www.meridianbioscience.com.
The link to the Conference is on our Investor Relations home page. The
archived broadcast will be available for 90 days.
Forward Looking Statements
The Private Securities Litigation Reform
Act of 1995 provides a safe harbor from civil litigation for
forward-looking statements accompanied by meaningful cautionary
statements. Except for historical information, this report contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, which may be identified by words such as
"estimates", "anticipates", "projects", "plans", "seeks", "may", "will",
"expects", "intends", "believes", "should" and similar expressions or
the negative versions thereof and which also may be identified by their
context. Such statements, whether expressed or implied, are based upon
current expectations of the Company and speak only as of the date made.
The Company assumes no obligation to publicly update or revise any
forward-looking statements even if experience or future changes make it
clear that any projected results expressed or implied therein will not
be realized. These statements are subject to various risks,
uncertainties and other factors that could cause actual results to
differ materially, including, without limitation, the following:
Meridian's continued growth depends, in part, on its ability to
introduce into the marketplace enhancements of existing products or new
products that incorporate technological advances, meet customer
requirements and respond to products developed by Meridian's
competition. While Meridian has introduced a number of internally
developed products, there can be no assurance that it will be successful
in the future in introducing such products on a timely basis. Ongoing
consolidations of reference laboratories and formation of multi-hospital
alliances may cause adverse changes to pricing and distribution.
Recessionary pressures on the economy and the markets in which our
customers operate can change expected results, as well as adverse trends
in buying patterns from customers. Costs and difficulties in complying
with laws and regulations administered by the United States Food and
Drug Administration can result in unanticipated expenses and delays and
interruptions to the sale of new and existing products. Changes in the
relative strength or weakness of the U.S. dollar can also change
expected results. One of Meridian's main growth strategies is the
acquisition of companies and product lines. There can be no assurance
that additional acquisitions will be consummated or that, if
consummated, will be successful and the acquired businesses successfully
integrated into Meridian's operations. In addition to the factors
described in this paragraph, Part I, Item 1A Risk Factors of our Form
10-K contains a list and description of uncertainties, risks and other
matters that may affect the Company which are incorporated by reference
into this press release.
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics manufacturers
and biotech companies in more than 60 countries around the world. The
Company’s shares are traded through NASDAQ’s Global Select Market,
symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700
Chief
Executive Officer
